Strattera ® (atomoxetine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Strattera® oral solution Administration Through a NG Tube

The administration of atomoxetine through a nasogastric (NG) tube has not been studied.

Further Information

The administration of atomoxetine through a nasogastric tube has not been studied, and no data are available regarding the safety of efficacy of this method of administration.

For approved posology and method of administration please refer to summary of product characteristics.1

References

1. Strattera Summary of Product Characteristics

Date of Last Review: 30 June 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request